From July 1, 2022 to September 30, 2022, the company has repurchased 1,716,300 shares, representing 0.18% for CNY 19.79 million. With this, the company has completed the repurchase of 1,716,300 shares, representing 0.18% for CNY 19.79 million under the buyback announced on June 10, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
11.85 CNY | -1.90% |
|
-2.23% | -2.55% |
May. 27 | ZBD Pharma Gets China Approval for Gastric Acid Inhibiting Tablets | MT |
May. 07 | China Grants Drug Registration Approval for ZBD Pharma's Anti-Epilepsy Injectable | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.55% | 1.53B | |
+41.68% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+17.96% | 246B | |
+0.33% | 225B | |
+10.66% | 218B | |
+3.68% | 160B | |
-4.38% | 156B |
- Stock Market
- Equities
- 603567 Stock
- News Heilongjiang ZBD Pharmaceutical Co., Ltd.
- Tranche Update on Heilongjiang ZBD Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 10, 2022.